Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 20, 2020
Daily News
October 20, 2020
- Sawai to Launch Zagallo Generic on Nov. 6
October 20, 2020
- Vice Health Minister Vows to Work on Law Amendment to Set Up Sound Vaccination Scheme
October 20, 2020
- Pfizer Starts Promotion for 4 Authorized Generics, Including Lyrica AG
October 20, 2020
- LEO Pharma’s Atopic Dermatitis Program Lags as PMDA Requests Japanese Data, but Growth Goal Intact
October 20, 2020
- Japan Cannot Boast of Its Development Status of COVID-19 Vaccines/Drugs: LDP Health Committee Chair
October 20, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…